基于治疗药物监测的抗生素方案在重症患者中的疗效:随机对照试验的系统评价与Meta分析
该系统评价与Meta分析纳入5项随机对照试验共1011例重症患者,评估基于治疗药物监测(TDM)的抗菌药物剂量优化策略的疗效。主要终点28天死亡率在TDM组与对照组间无显著差异(RR 0.94,95%CI 0.77-1.14;I²=0%)。院内死亡率、临床治愈、ICU住院时间及第1天和第3天目标达成率均无显著差异,次要结局证据确定性为低或极低。作者结论认为TDM方案对临床或药理结局无显著疗效,需进一步研究。
要点
- 5项RCT共1011例重症患者,TDM方案与对照组28天死亡率无显著差异(RR 0.94,95%CI 0.77-1.14;I²=0%)。
- 院内死亡率无显著差异(RR 0.96,95%CI 0.76-1.20),临床治愈无显著差异(RR 1.23,95%CI 0.91-1.67)。
- ICU住院时间无显著差异(均数差0,95%CI -2.18-2.19)。
- 第1天目标达成率(RR 1.14,95%CI 0.88-1.48)和第3天目标达成率(RR 1.35,95%CI 0.90-2.03)均无显著差异。
- 次要结局证据确定性为低或极低,因纳入研究存在严重偏倚风险、结局定义差异及样本量小;作者认为需进一步研究。
适用人群与场景
- 重症患者(纳入随机对照试验的重症患者人群)
研究设计与关键结果
- 研究类型:随机对照试验的系统评价与Meta分析,共纳入5项研究、1011例患者。
- 主要终点28天死亡率:TDM方案组与对照组无显著差异(RR 0.94,95%CI 0.77-1.14;I²=0%)。
- 院内死亡率:两组无显著差异(RR 0.96,95%CI 0.76-1.20)。
- 临床治愈:两组无显著差异(RR 1.23,95%CI 0.91-1.67)。
- ICU住院时间:两组无显著差异(均数差0,95%CI -2.18-2.19)。
- 第1天目标达成率:两组无显著差异(RR 1.14,95%CI 0.88-1.48)。
- 第3天目标达成率:两组无显著差异(RR 1.35,95%CI 0.90-2.03)。
- 次要结局证据确定性均为低或极低,因纳入研究存在严重偏倚风险、结局定义差异及样本量小。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与Meta分析;采用Cochrane随机试验偏倚风险评估工具第二版评估偏倚风险,采用GRADE方法对证据质量进行分级。
- 局限:纳入研究存在严重偏倚风险、结局定义存在差异、样本量小;次要结局证据确定性为低或极低。
- 作者结论:TDM方案对临床或药理结局无显著疗效,需进一步研究其他可达到的目标和明确定义的结局。
对床旁实践的改变
- 作者认为,基于TDM的抗生素方案对临床或药理结局无显著疗效,需进一步研究其他可达到的目标和明确定义的结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The efficacy of therapeutic drug monitoring (TDM)-based antimicrobial dosing optimization strategies on pharmacokinetics/pharmacodynamics and specific drug properties for critically ill patients is unclear. Here, we conducted a systematic review and meta-analysis of randomized controlled trials to evaluate the effectiveness of TDM-based regimen in these patients.
METHODS: Articles from three databases were systematically retrieved to identify relevant randomized control studies. Version two of the Cochrane tool for assessing risk of bias in randomized trials was used to assess the risk of bias in studies included in the analysis, and quality assessment of evidence was graded using the Grading of Recommendations Assessment, Development, and Evaluation approach. Primary outcome was the 28-day mortality and secondary outcome were in-hospital mortality, clinical cure, length of stay in the intensive care unit (ICU) and target attainment at day 1 and 3.
RESULTS: In total, 5 studies involving 1011 patients were included for meta-analysis of the primary outcome, of which no significant difference was observed between TDM-based regimen and control groups (risk ratio [RR] 0.94, 95% confidence interval [CI]: 0.77-1.14; I2 = 0%). In-hospital mortality (RR 0.96, 95% CI: 0.76-1.20), clinical cure (RR 1.23, 95% CI: 0.91-1.67), length of stay in the ICU (mean difference 0, 95% CI: - 2.18-2.19), and target attainment at day 1 (RR 1.14, 95% CI: 0.88-1.48) and day 3 (RR 1.35, 95% CI: 0.90-2.03) were not significantly different between the two groups, and all evidence for the secondary outcomes had a low or very low level of certainty because the included studies had serious risk of bias, variation of definition for outcomes, and small sample sizes.
CONCLUSION: TDM-based regimens had no significant efficacy for clinical or pharmacological outcomes. Further studies with other achievable targets and well-defined outcomes are required.
TRIAL REGISTRATION: Clinical trial registration; PROSPERO ( https://www.crd.york.ac.uk/prospero/ ), registry number: CRD 42022371959. Registered 24 November 2022.
参考来源
- Takahashi N, Kondo Y, Kubo K, et al. Efficacy of therapeutic drug monitoring-based antibiotic regimen in critically ill patients: a systematic review and meta-analysis of randomized controlled trials. J Intensive Care. 2023. PMID: 37936203. doi:10.1186/s40560-023-00699-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。